Omega Medical Imaging first in the world to receive FDA clearance on artificial intelligence imaging system that reduces dose

171
dose
Omega FluoroShield

Omega Medical Imaging, manufactures of Artificial Intelligence Fluoroscopy/Cine (AIF/C) Imaging systems, has announced US Food and Drug Administration (FDA) 510(k) clearance of FluoroShield with their 2020 cardiac flat panel detector.

The FluoroShield system allows for auto-collimation during interventional fluoroscopy or cine cases, while maintaining a perspective of the surrounding anatomy. The blended image incorporates a lower frequency refresh of the peripheral image area, a press release explains. This combined image (live fluoroscopy or cine and background refreshed at a rate of once or twice per second) increases the quality of information presented during interventional procedures.

Brian Fleming, president of Omega Medical Imaging, states, “Until now, products on the market have only been able to manage radiation to patients and staff. FluoroShield is the only system in the world that provides an actual reduction in dose. The impact of this ground-breaking solution for patients and healthcare providers is substantial. I am very grateful to be a part of a team that pushes the envelope in the development of safer healthcare solutions.”


LEAVE A REPLY

Please enter your comment!
Please enter your name here